BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 10914214)

  • 21. M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Whitmore WF; Herr HW; Morse MJ; Sogani PC; Watson RC; Hollander PS; Fair WR
    Prog Clin Biol Res; 1988; 260():481-5. PubMed ID: 3283768
    [No Abstract]   [Full Text] [Related]  

  • 22. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
    Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Combination chemotherapy of methotrexate, etoposide, adriamycin and cisplatin (M-EAP) for advanced urothelial cancer].
    Hashimura T; Okumura K; Akao T; Nakagawa T
    Hinyokika Kiyo; 1991 Jul; 37(7):685-8. PubMed ID: 1927767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Geller N; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N
    Cancer; 1989 Dec; 64(12):2448-58. PubMed ID: 2819654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma.
    Balbay MD; Ozen H; Uluçay S; Sahin A; Ergen A; Koçal C; Remzi D
    Int Urol Nephrol; 1993; 25(4):351-7. PubMed ID: 8276565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma.
    Mulatero C; McClaren BR; Mason M; Oliver RT; Gallagher CJ
    Br J Cancer; 2000 Dec; 83(12):1612-6. PubMed ID: 11104554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
    de Vries RR; Nieuwenhuijzen JA; Meinhardt W; Bais EM; Horenblas S
    Eur J Surg Oncol; 2009 Apr; 35(4):352-5. PubMed ID: 18722076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)].
    Bellmunt Molins J; Ribas A; Albanell J; Lorente Garín JA; de Torres Mateos JA; Morote Robles J; López Palacios MA; Banús Gassol JM; Casado Cobo S; Eres N; Solé Calvo LA
    Arch Esp Urol; 1996 Jun; 49(5):465-72. PubMed ID: 8766083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chemotherapy of metastatic cancer of the bladder. Apropos of 50 patients treated with M-VAC].
    Beuzeboc P; Dhote R; Thiounn N; Flam T; Zerbib M; Debré B; Pouillart P
    Cancer Radiother; 1998 Apr; 2 Suppl 1():92s-96s. PubMed ID: 9749087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N; Weiselberg LR
    J Urol; 1988 Mar; 139(3):461-9. PubMed ID: 3343727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radical chemoradiotherapy for elderly patients with bladder carcinoma invading muscle.
    Arias F; Dueñas M; Martínez E; Domínguez MA; Illarramendi JJ; Villafranca E; Tejedor M; Molina F; Meiriño R; Valerdi JJ
    Cancer; 1997 Jul; 80(1):115-20. PubMed ID: 9210716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
    J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
    Igawa M; Kadena H; Ohkuchi T; Ueda M; Usui T
    Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1627-36. PubMed ID: 1770701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
    Stöckle M; Meyenburg W; Wellek S; Voges G; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    Ann Urol (Paris); 1993; 27(1):51-7. PubMed ID: 7682388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chemotherapy of invasive bladder cancer].
    Kotake T
    Gan To Kagaku Ryoho; 1991 Nov; 18(14):2375-82. PubMed ID: 1952956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis.
    Kobayashi H; Obata K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S14-7. PubMed ID: 7994781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
    Miyanaga N; Akaza H; Shimazui T; Ohtani M; Koiso K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S5-8. PubMed ID: 7527735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.